MedTrace Logo

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

NCT00851929 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-08-02

No results posted yet for this study

Summary

Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis

Conditions

  • Sarcoidosis
  • Pulmonary Hypertension

Interventions

DRUG

Ambrisentan

ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Marc A Judson, MD · Medical University of South Carolina

  • Don C Rockey, MD · Medical University of South Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-04-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00851929 on ClinicalTrials.gov